Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis.
Abstract
Clinical trials have suggested that patients with myeloma treated with lenalidomide may have an increased risk of second primary malignancies (SPM). Whether such risks are of significant relevance in the real-world clinical practice, particularly among older patients receiving first-line lenalidomide based therapy, remains unclear. Using Surveillance Epidemiology and End Results-Medicare database, we identified adults ≥ 65 years with plasma cell myeloma diagnosed in 2007-2015 who received at least one oral anti-myeloma agent. We defined first-line lenalidomide-containing therapy as use within 90 days of diagnosis. SPM was defined as a malignancy reported to a cancer registry > 90 days after myeloma diagnosis. We computed cumulative incidence of SPM (with death being a competing event) and compared SPM rates between patients treated with or without first-line lenalidomide using a Fine-Gray's model, adjusting for age, sex, race, ethnicity, prior malignancy, and histologic subtype. Of 9850 Medicare beneficiaries, 4009 (41%) received first-line lenalidomide. During median follow up of 5.0 years, 423 patients (4.3%) developed SPM, including 361 solid tumors (85%) and 61 hematologic malignancies (14%). The cumulative incidence of any...Continue Reading
References
Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma
Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide
Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study
Related Concepts
Related Feeds
Cancer Disparities
Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.